The development of graft-vs-host disease (GVHD) limits the effectiveness of DLI in patients (pts) who have relapsed after allogeneic BMT. Several studies suggest that the depletion of CD8+ cells prior to DLI may lead to a reduction in the incidence and severity of GVHD. A prospective comparative trial between CD8-depleted and non-depleted DLI should be performed to confirm this finding; however, current methods to deplete large number of cells from pheresis products are time consuming and difficult to perform. Recently, CD8 murine monoclonal antibody-coated dense nickel particles have been developed which allow for the rapid separation of cells by use of gravity. We conducted a pilot trial using CD8-High Density Microparticles (HDM) to determine the efficacy of CD8 depletion and the safety of infusing cells processed by this method. All pts received 3.0 × 10 7 CD4+ cell/kg, a dose that had been defined in previous studies. No other immune modulating therapy was used. Nine pts who relapsed after allogeneic BMT were enrolled. Three pts had CML, 3 multiple myeloma, 2 CLL and 1 NHL. The median age was 40 (range 31-58) and the median time from transplant to DLI was 43 months (range 10-78). Two pts (1 multiple myeloma, 1 NHL) were withdrawn from the study due to rapidly progressive disease. Neither patient had evidence of toxicity related to DLI. Eight of 9 pts received the targeted cell number after 1 pheresis procedure. The time required for processing with CD8-HDM was approximately 1 hour. The median depletion of CD8+ cells from the pheresis product was 100% (range 97.8 to 100%); the mean percent yield of CD4+ cells was 105%. With depletion of CD8+ cells, the mean yield of CD3+ cells was 72.2%. No infusional toxicity related to the method of depletion was noted. One patient developed interstitial pneumonitis 2 weeks following cell infusion, which resolved. The overall incidence and severity of GVHD was low: 1 pt developed grade 2 acute GVHD and limited chronic GVHD. Two of 3 pts with CML developed a complete cytogenetic response with the remaining pt demonstrating a complete hematologic response. One pt with CLL had a CR. The remaining patients had progressive disease. CD8-HDM appears to be highly selective and effective in depleting CD8+ cells from pheresis products.
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Case Report: We report a life-threatening hemolysis of a 1-year-old child with FEL shortly after engraftment. The child received allogeneic-related PBSCT with AB0-mismatch (patient's blood type B pos., donor A pos.) after Bu/Cy-conditioning therapy. A total of 11.46 × 10 6 /kg CD34+ cells was transfused. MTX and CSA were given as GvHD prophylaxis. Engraftment criteria were met on day +10. On day +13, serum Hb dropped within 10 hrs from 11.5 to 4.5 g/dl. No source of acute bleeding could be found. Direct Coombstest was positive. Haptoglobin fell below detection level. LDH transiently rose to 2000 U/l, and total bilirubin to over 1100 mol/l. The child acutely developed ketoacidotic shock and respiratory insufficiency. The further course of the child was complicated by prolonged hyperbilirubinemia, interstitial pneumonia and a re-activated CMV-infection. Discussion: Recent data of transplantations with AB0-mismatched grafts with AB0-minor mismatch component suggest an association with engraftment and proliferation of B-lymphocytes with hemolysis of host erythrocytes.
1,2 In a retrospective analysis, 1 patient out of 15 patients with AB0-minor mismatched transplantation at our institution showed intravasal hemolysis during the first week after transplantation, and 4 patients until day +56.
3 Our own data and data from other centers give evidence that severity of hemolysis is associated to transplantation of PBSC rather than BM, high CD34+ cell count in the graft, early engraftment, and T-cell suppression or depletion. Otherwise, hemolysis appears to be rather subclinical. Conclusion: 1. We emphasize the importance of close immunohematological monitoring of patients especially in AB0-mismatched PBSCT and T-cell suppression. 2. Blood transfusions after AB0-minor incompatible transplantation should be packed red blood cells of the donor's blood type. 3. Future research has to concentrate on possible indications and means for B-cell suppression and specific T-cell suppression. 1. Wernet D et al. Beitr Infusionsther 1992; 30:359-62, 2. Oziel-Taieb S et al., Bone Marrow Transplant 1997; 19:1155 -6, 3. Nürnberger W et al., Sept. 1998 The BMT Program at the Heinrich Heine University is supported by the Elterninitiative Kinderkrebsklinik e.V. Düsseldorf.
